非執行董事 傅唯先生 （ 榮譽主席 ） 曹基哲先生 獨立非執行董事 徐海音女士 李軼梵先生 蔣世東先生 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 董事名單及其角色和職能 雲頂新耀有限公司（「本公司」）的董事會（「董事會」）成員載列如下。 執行董事 吳以芳先生 （ 主席 ） 羅永慶先生 （ 首席執行官 ） 何穎先生 （ 總裁、首席財務官 ） 董事會設有三個委員會。下表載列該等委員會的成員詳情。 | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 吳以芳先生 | | 成員 | 主席 | | 羅永慶先生 | | | | | 何穎先生 | | | | | 傅唯先生 | | | | | 曹基哲先生 | | | | | 徐海音女士 | 成員 | 主席 | 成員 | | 李軼梵先生 | 主席 | | 成員 | | 蔣世東先生 | 成員 | 成員 | | 香港，2025年10月10日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 董事、董事會主席以及提名委員會和 薪酬委員會組成之變動及 委任榮譽主席 董事會宣佈，自2025年10月10日起： 董事調任、委任執行董事、董事會主席以及提名委員會和薪酬委員會組成 之變動及委任榮譽主席 雲頂新耀有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，傅唯先生（「傅先 生」）已調任為非執行董事，並不再擔任董事會主席、提名委員會（「提名委員會」） 主席及薪酬委員會（「薪酬委員會」）成員，各項變動均自2025年10月10日起生效， 以投放更多時間處理其他事務。 – 1 – 1. 傅先 生 已 調任 為 本 公司 非 執 行董 事 ， 並 不再 擔 任 董事 會 主 席、 提 名 委員 會 主席及薪酬委員會成員； 2. 傅先生已獲委任為董事會榮譽主席； ...

Core Insights - The innovative drug Etrasimod (VELSIPITY) developed by the company for treating moderate to severe active ulcerative colitis (UC) has shown promising results in the ENLIGHT UC Phase III clinical study, published in The Lancet Gastroenterology & Hepatology [1][2] - The study demonstrated a mucosal healing rate of 51.9% and a complete normalization rate of 45.5% after 52 weeks of treatment, significantly higher than the current 24% rate among patients achieving mucosal healing [1][3] - Etrasimod is anticipated to reach peak sales of 5 billion yuan, positioning it as a key product alongside the company's existing offerings in the autoimmune disease sector [1][5] Study Details - The ENLIGHT UC study was a multicenter, randomized, double-blind, placebo-controlled trial involving 340 patients who had previously failed or were intolerant to standard treatments for UC [2][3] - Results indicated statistical significance and clinical relevance across all primary and secondary efficacy endpoints during both the 12-week induction and 40-week maintenance phases [2] Clinical and Market Implications - The increasing prevalence of UC in Asia, with an estimated 800,000 patients in China by 2024 projected to rise to nearly 1.5 million by 2031, highlights the urgent clinical need for effective treatments [3][4] - Etrasimod's mechanism as a high-selectivity oral S1P receptor modulator aligns with the core treatment needs for UC, offering advantages such as rapid onset of action and deep mucosal healing [4][5] - The drug has been recognized in clinical guidelines, being recommended as a first-line treatment for UC by the American Gastroenterological Association and the American College of Gastroenterology [4][5] Commercialization Progress - Etrasimod has received approvals in regions such as Macau, Singapore, and Hong Kong, with new drug applications (NDA) accepted in Taiwan and South Korea [5] - The company has initiated local production in Zhejiang, aiming for an annual capacity of 50 million tablets to ensure supply [5] - The NDA for Etrasimod in mainland China is expected to be approved by mid-2026, which will benefit domestic patients [5]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 雲頂新耀有限公司 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01952 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 第 1 ...

Core Points - Company announced the grant of a total of 74,000 stock options under the post-IPO stock option plan [1] - Additionally, the company granted a total of 234,800 awards under the pre-IPO employee stock option plan [1]

智通财经APP讯，云顶新耀(01952)发布公告，于2025年10月2日，董事会(i)根据首次公开发售后购股权 计划合共授出7.4万份购股权;及(ii)根据首次公开发售前雇员购股权计划合共授出23.48万份奖励。 ...

Core Viewpoint - The company, CloudTop New Horizon (01952.HK), announced the granting of stock options and employee stock options as part of its incentive plans following its initial public offering [1] Group 1 - The board granted a total of 74,000 stock options under the post-IPO stock option plan [1] - Additionally, a total of 234,800 reward options were granted under the pre-IPO employee stock option plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 授出購股權及獎勵 本公告乃根據上市規則第17.06A、17.06B及17.06C條刊發。 於2025年10月2日，董事會(i)根據首次公開發售後購股權計劃合共授出74,000份購 股權；及(ii)根據首次公開發售前僱員購股權計劃合共授出234,800份獎勵。有關上 述授出的詳情如下： (1) 授出購股權 董事會宣佈，於2025年10月2日，本公司根據首次公開發售後購股權計劃向購 股權承授人授出74,000份購股權。 授出購股權的詳情如下： 授出日期： 2025年10月2日 購股權承授人數目： 3名 所授出購股權的數目： 74,000份 所授出購股權的行使價： 57.50港元 股份於授出日期的市價： 每股股份57.50港元 行使期： 授出日期起計7年 – 1 – 歸 ...

Core Viewpoint - Genting Yongying (01952) has seen a significant increase in stock price, attributed to the approval of production expansion for its core product, Naisfankang, and its inclusion in a global kidney disease management guideline, indicating a strategic shift in treatment options for IgA nephropathy patients [1] Group 1: Financial Performance - Genting Yongying's stock rose over 6%, currently up 5.39% at HKD 57.65, with a trading volume of HKD 300 million [1] - Naisfankang's sales revenue reached HKD 520 million in August, with a shipment volume exceeding 100,000 bottles, marking a new monthly high since its launch [1] - The company has raised its revenue guidance for the full year 2025 to HKD 1.2-1.4 billion, with expectations to further increase it to HKD 2.4-2.6 billion in 2026 [1] Group 2: Product Development and Market Position - The production expansion application for Naisfankang was approved by the National Medical Products Administration in early August, allowing the company to resume its sales growth [1] - On September 19, Genting Yongying announced that Naisfankang was included in the 2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis, becoming the only recommended treatment for IgA nephropathy in the guideline [1] - The inclusion in the KDIGO guidelines is seen as a significant milestone, providing new treatment options for IgA nephropathy patients and indicating a shift in global treatment strategies [1]

Core Viewpoint - CloudTop New Horizon (01952) has seen a significant increase in stock price, rising over 6% in the afternoon trading session, attributed to the approval of production expansion for its core product, Naisukan, and its inclusion in a global kidney disease management guideline [1] Group 1: Financial Performance - Naisukan's sales revenue reached 520 million yuan in August, marking a record high for monthly sales since its launch, with over 100,000 bottles shipped [1] - The company has raised its revenue guidance for the full year 2025 to 1.2-1.4 billion yuan, with expectations to further increase to 2.4-2.6 billion yuan in 2026 [1] Group 2: Regulatory and Market Developments - The production expansion application for Naisukan was approved by the National Medical Products Administration in early August, allowing the company to resume its sales growth [1] - On September 19, Naisukan was included in the 2025 KDIGO Clinical Practice Guidelines for IgA Nephropathy and IgA Vasculitis, becoming the only recommended treatment for IgA nephropathy in the guideline, indicating a shift in global treatment strategies [1]